Business Wire

Andersen Global Solidifies Presence in Malta with Member Firm Addition

Share

Andersen Global continues to strengthen its presence in Europe through the establishment of Andersen in Malta. Together, with existing member law firm Chetcuti Cauchi Advocates, the firms will provide a comprehensive suite of integrated tax, legal, and corporate services to private and business clients in Malta and internationally.

Andersen in Malta provides a wide range of services, including personal and corporate tax advisory and tax compliance services, transfer pricing, data compliance, global mobility and HNW immigration, estate planning, private wealth structuring, family business advisory and business advisory services. The firm specializes in navigating complex regulatory and tax frameworks and advises high-net-worth individuals, family offices, and multinational businesses.

“As Malta evolves as a reliable destination for private wealth structuring and business expansion in Europe, our firms remain committed to providing quality, client-focused services,” said Jean-Philippe Chetcuti, Managing Partner of Andersen in Malta and Chetcuti Cauchi Advocates. “We will be able to leverage the Andersen Global platform and expand our capabilities to offer seamless, multidisciplinary and cross-border solutions to our clients.”

Global Chairman and CEO of Andersen Mark L. Vorsatz added, “The team in Malta has demonstrated a strong commitment to excellence and a deep understanding of the local market. Their combined expertise enhances our ability to deliver integrated services in the region and supports our strategy to strengthen our presence in Europe.”

Andersen Global is an international association of legally separate, independent member firms comprised of tax, legal, and valuation professionals around the world. Established in 2013 by U.S. member firm Andersen Tax LLC, Andersen Global now has more than 18,000 professionals worldwide and a presence in over 500 locations through its member firms and collaborating firms.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241204795138/en/

Contacts

Megan Tsuei
Andersen Global
415-764-2700

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pacific Avenue Capital Partners Establishes Paris France Office and Xavier Lambert Joins as Head of Europe to Lead Firm’s EU Expansion10.12.2024 08:00:00 CET | Press Release

Pacific Avenue Capital Partners, LLC (“Pacific Avenue”), a Los Angeles-headquartered private equity firm focused on corporate divestitures, carve-outs, and other complex situations in the middle market, announced today the opening of a European office in Paris, France. The office will be led by Xavier Lambert, who joins the firm as Managing Director – Head of Europe. Opening a Paris office underscores Pacific Avenue's continued focus on being a solutions provider to corporate sellers globally. With increasing carve-out and divestiture activity globally, and a growing number of Pacific Avenue’s deals with international operations, establishing a presence in Europe is a natural step in fulfilling the firm’s strategy. The addition of Mr. Lambert will expand the firm’s international footprint and add capabilities to serve global corporate sellers and Pacific Avenue businesses with international operations. "Expanding our footprint in Europe marks a pivotal milestone in Pacific Avenue’s gro

Media Release: Allianz lifts financial ambitions at its Capital Markets Day 202410.12.2024 07:07:00 CET | Press Release

Outperforming on key 2024 financial targets, Allianz has set ambitious financial targets through 2027 at its Capital Markets Day 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209829384/en/ Oliver Bäte, Chief Executive Officer of Allianz SE (Photo: Allianz SE) In a world of uncertainty, Allianz aims to capitalize on its role as a trusted partner of choice by growing its customer base with innovative protection and retirement solutions and seamless services. Allianz will focus on three levers to sustain its strong value creation momentum. First, driving smart growth by winning new customers, increasing cross-sell, and reducing churn. Second, reinforcing productivity through continuous delivery of its productivity agenda, also leveraging latest generative AI solutions. Third, strengthening business and financial resilience, supported by a refined capital management framework. Oliver Bäte, Chief Executive Officer of Al

Sirius Therapeutics Announces Promising Phase I Clinical Data from Its Factor XI siRNA, a Long-Acting Next-Generation Anticoagulant for Thromboembolic Disorders10.12.2024 05:00:00 CET | Press Release

Sirius Therapeutics today announced promising preliminary data from its Phase 1 first-in-human clinical trial of SRSD107, a next generation siRNA therapeutics under clinical development for the prevention and treatment of thromboembolic disorders, such as myocardial infarction, ischemic stroke, and venous thromboembolism. The trial data were presented during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, held in San Diego, CA. SRSD107 is designed to inhibit Factor XI (FXI), a protein in the coagulation pathway that has shown potential to reduce thrombosis without significantly increasing the risk of bleeding, a major liability of current drugs. “In this trial, SRSD107 was safe and well tolerated, with pharmacokinetic parameters consistent with a typical siRNA product,” said Dr. Patrick Yue, Sirius’ Chief Medical Officer. “We are encouraged by the marked, prolonged reduction in FXI antigen and activity, and increase in clotting, or throm

Mori Memorial Foundation Issues GPCI – 2024 and GPCI – Financial Centers Reports:10.12.2024 04:00:00 CET | Press Release

The Mori Memorial Foundation’s Institute for Urban Strategies, a research body established by Mori Building, Tokyo’s leading urban landscape developer, today released its Global Power City Index (GPCI) 2024 report on the overall strength of the world’s 48 major cities. For the second time, the report additionally includes the 'GPCI–Financial Centers' index. This index reflects the growing importance of measures taken by major cities to enhance their status as international financial centers, capturing changes in their financial and business environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241209714811/en/ The 48 major cities evaluated in Mori Memorial Foundation’s GPCI–2024 Report (Graphic: Business Wire) More than 18 months have elapsed since the World Health Organization declared an end to the COVID-19 pandemic in May 2023. With the resurgence of economic activity, mobility and the expansion of international to

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA ® and Novel Pipeline Assets10.12.2024 02:30:00 CET | Press Release

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that plans to change its name to BeOne Medicines Ltd., today announced the presentation of new clinical data at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, underscoring its leadership in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) through continued clinical success with BRUKINSA® (zanubrutinib) and promising advancements in its pipeline assets. “The breadth of data we’re presenting at ASH underscores BRUKINSA’s role as a best-in-class treatment for CLL and highlights BeiGene’s leadership in advancing the treatment landscape for B-cell malignancies,” said Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “BRUKINSA shows tremendous promise for patients as a monotherapy and as a backbone for best-in-class combinations. The combination of BRUKINSA and our investigational BCL2 inhibitor, sonrotoclax, demonstrated significant pot

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye